Boston Scientific Corp
NYSE:BSX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (7.2), the stock would be worth $100.33 (62% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.5 | $62.07 |
0%
|
| 3-Year Average | 7.2 | $100.33 |
+62%
|
| 5-Year Average | 5.8 | $80.88 |
+30%
|
| Industry Average | 1.7 | $24.25 |
-61%
|
| Country Average | 2.4 | $33.86 |
-45%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$92B
|
/ |
Apr 2026
$20.6B
|
= |
|
|
$92B
|
/ |
Dec 2026
$22.5B
|
= |
|
|
$92B
|
/ |
Dec 2027
$24.7B
|
= |
|
|
$92B
|
/ |
Dec 2028
$27.2B
|
= |
|
|
$92B
|
/ |
Dec 2029
$29.8B
|
= |
|
|
$92B
|
/ |
Dec 2030
$33.3B
|
= |
|
|
$92B
|
/ |
Dec 2031
$36.8B
|
= |
|
|
$92B
|
/ |
Dec 2032
$40.8B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 4.5 | 25.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 17 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 3.5 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 5 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 3 | 23.2 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 7.8 | 44.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 1.7 | 19 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 10.5 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 2 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 5.9 | 21.6 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
31.4B USD | 1.5 | 15.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Boston Scientific Corp
Glance View
In the world of medical devices, Boston Scientific Corp. has carved out a significant niche, navigating the intersection of innovation and healthcare with precision. Founded in 1979, the company has built a robust reputation for developing a diverse range of products that address complex medical conditions. Boston Scientific operates through various segments, primarily focusing on interventional medical specialties that target areas such as cardiology, endoscopy, and neuromodulation. Through its relentless pursuit of innovation, the company continues to push boundaries, enhancing the diagnostic and therapeutic capabilities of physicians worldwide. The heartbeat of its operations lies in its extensive research and development endeavors, where cutting-edge technology meets advanced medical knowledge to produce life-enhancing solutions. At its core, Boston Scientific makes money by designing, manufacturing, and selling medical devices used in minimally invasive procedures. Its product portfolio includes solutions for coronary artery disease, heart rhythm disorders, peripheral artery disease, and many other critical ailments. By partnering with healthcare providers, Boston Scientific enables hospitals and clinics to offer high-quality, efficient care that caters to patient needs in a cost-effective manner. Revenue streams flow through direct sales channels and strategic partnerships across global markets, reflecting a combination of organic growth and strategic acquisitions. Moreover, the company actively reinvests in future technologies, ensuring its position as a pioneer in medical advancements while meeting the ever-evolving demands of the industry.